<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856476</url>
  </required_header>
  <id_info>
    <org_study_id>234</org_study_id>
    <nct_id>NCT03856476</nct_id>
  </id_info>
  <brief_title>The Effect of Childhood Dyslipidemia on Endothelial and Renal Function</brief_title>
  <official_title>Early Markers of Endothelial and Renal Dysfunction in Children With Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Ioannina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Ioannina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Ioannina</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess if abnormal lipid levels in childhood could cause early&#xD;
      damage of the inner layer of the vessels, the endothelium. Dysfunction of the endothelium is&#xD;
      the first event in the development of atherosclerosis, is present at all stages of&#xD;
      atherosclerosis and is potentially reversible in childhood. It has been suggested that&#xD;
      dyslipidemia, via its detrimental effects on endothelium, could impair renal function. This&#xD;
      study will assess the dysfunction of the kidneys in children with dyslipidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In children recruited in the study, family history of dyslipidemia or premature&#xD;
      cardiovascular disease will be recorded. Furthermore, anthropometric and clinical&#xD;
      characteristics will be noted and lipid measurements will be obtained at recruitment after a&#xD;
      fasting period.&#xD;
&#xD;
      The investigators will test in children the flow-mediated dilation (FMD) which assesses the&#xD;
      vasodilation due to the production of nitric oxide from the endothelium in response to&#xD;
      occlusion-induced hyperaemia of the branchial artery and the carotid intima-media thickness&#xD;
      (cIMT). These non-invasive ultrasound indices detect early vascular damage.&#xD;
&#xD;
      Renal function will be assessed in children with dyslipidemia by a new marker in serum,&#xD;
      cystatin C, which is more accurate and reliable than creatinine. Also, creatinine serum&#xD;
      levels and estimated glomerular filtration rate (eGFR) will be evaluated. Additionally, total&#xD;
      protein, albumin, electrolyte and β2-microglobulin excretion in urine will be measured.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 3, 2017</start_date>
  <completion_date type="Actual">April 3, 2020</completion_date>
  <primary_completion_date type="Actual">April 3, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Flow-mediated dilation of the branchial artery</measure>
    <time_frame>At subject enrollment</time_frame>
    <description>Non-invasive ultrasound assessment of endothelial function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Carotid intima-media thickness</measure>
    <time_frame>At subject enrollment</time_frame>
    <description>Non-invasive ultrasound assessment of early vascular disease.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of cystatin C in serum</measure>
    <time_frame>At subject enrollment</time_frame>
    <description>Cystatin C is a marker for assessing renal function</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal levels of lipoprotein a.</measure>
    <time_frame>At subject enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels of β2-microglobulin in urine</measure>
    <time_frame>At subject enrollment</time_frame>
    <description>Assessment of tubular function of the kidneys.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine levels</measure>
    <time_frame>At subject enrollment</time_frame>
    <description>Assessment of renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of eGFR</measure>
    <time_frame>At subject enrollment</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Dyslipidemias</condition>
  <condition>Children, Only</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Renal Dysfunction</condition>
  <condition>Hypercholesteremia in Children</condition>
  <arm_group>
    <arm_group_label>Dyslipidemia group</arm_group_label>
    <description>Children and adolescents with dyslipidemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Children and adolescents without dyslipidemia</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The group of children with dyslipidemia will be selected from children referred to the&#xD;
        Outpatient Lipid Clinic for Children and Adolescents and to the Pediatric Nephrology&#xD;
        Department of the University Hospital of Ioannina. These are centers of excellence for&#xD;
        assessing children with dyslipidemia and renal function in Northwestern Greece.&#xD;
&#xD;
        The referrals are due to abnormal lipid levels in routine blood samples or family history&#xD;
        of dyslipidemia and/or family history of premature cardiovascular disease.&#xD;
&#xD;
        The group of controls will be selected from children attending the Outpatient Pediatric&#xD;
        Clinic of University Hospital of Ioannina for follow-up of headache, heart murmur,&#xD;
        constipation and loss of consciousness.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Children and adolescents aged 7 to 17 years&#xD;
&#xD;
          -  Dyslipidemia (serum levels of LDL-cholesterol ≥95th percentile or serum levels of&#xD;
             triglycerides ≥95th percentile or serum levels of HDL-cholesterol ≤5th percentile for&#xD;
             age and sex)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of renal disease&#xD;
&#xD;
          -  Dyslipidemia caused by nephrotic syndrome or chronic kidney disease&#xD;
&#xD;
          -  Chronic use of medication&#xD;
&#xD;
          -  Acute or chronic inflammatory process&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Ioannina</name>
      <address>
        <city>Ioánnina</city>
        <zip>45500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Kosmeri C, Siomou E, Vlahos AP, Milionis H. Review shows that lipid disorders are associated with endothelial but not renal dysfunction in children. Acta Paediatr. 2019 Jan;108(1):19-27. doi: 10.1111/apa.14529. Epub 2018 Aug 22.</citation>
    <PMID>30066344</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>November 2, 2020</last_update_submitted>
  <last_update_submitted_qc>November 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Ioannina</investigator_affiliation>
    <investigator_full_name>Chrysoula Kosmeri</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

